MRK — long thesis
Thesis
MRK defensive healthcare — partial profit-take EXECUTED Aug 19 per the thesis's own terms (the Moderna-Merck cancer-vaccine Phase 3 win gapped the stock through the 10-12% take-profit band; ~45% was sold into strength). The retained core is now managed on the post-catalyst trail, not the old cost-based band. The catalyst continues to compound favorably: Aug 20 coverage frames the Phase 3 win as raising the competitive stakes in personalized cancer vaccines with Merck/Moderna in the lead — durable Keytruda-franchise validation, not a one-day squeeze. Healthcare remains the strongest 5d sector (+3.0%) despite a red Aug 20 session (-1.3% 1d). Hold the core as defensive ballast.
Triggers
Entry: Position already held — managed as core defensive ballast. Prior formation-entry language retired.
Exit: Partial profit-take COMPLETED Aug 19 — do not re-trim on the same trigger. Remaining core: trail stop at $135 (exit on a close below), full take-profit above $165, trim if healthcare underperforms SPY for 3+ consecutive weeks.
Invalidation: Close below $130 on volume (post-catalyst gap fully faded). The cancer-vaccine program hits a regulatory snag or the data unravels on full readout. Major adverse action on the Keytruda franchise. Healthcare underperforms SPY for 3+ consecutive weeks.
Cited evidence
News
- MRK Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)
- MRK Moderna's Cancer Vaccine Win Is Merck's Story Too
- MRK Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy
Macro
- Nasdaq 100 Plunges Over 3% On Rate Hike Jitters, Bitcoin's Bloodbath Worsens: Stock Market Today
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Fed's Daly Speaking On Bloomberg Says Most Worrying Today Is Getting Inflation Back To Target, Number One Priority
- Ed Yardeni's Fed Bombshell: Rate Hike Coming In July
- Ceasefire Agreed On By The U.S. And Iran In Early April Would Be Extended For 60 Days
- Mohamed El-Erian Warns Investors Can No Longer Count On Central Banks To Rescue Markets During Selloffs
- FDA Approves First Treatment For Chronic Hepatitis Delta Virus (HDV) Infection